Free Trial
NASDAQ:AXNX

Axonics Q3 2024 Earnings Report

Axonics EPS Results

Actual EPS
$0.16
Consensus EPS
$0.11
Beat/Miss
Beat by +$0.05
One Year Ago EPS
$0.08

Axonics Revenue Results

Actual Revenue
$116.19 million
Expected Revenue
$113.36 million
Beat/Miss
Beat by +$2.83 million
YoY Revenue Growth
+24.80%

Axonics Announcement Details

Quarter
Q3 2024
Time
After Market Closes
Conference Call Date
Thursday, November 7, 2024
Conference Call Time
3:00PM ET

Axonics Earnings Headlines

Axonics Modulation Technologies Merges and Delists from Nasdaq
URGENT: This Altcoin Opportunity Won’t Wait – Act Now
My friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92% win rate trading system is built to profit in any market – whether Bitcoin is mooning, correcting, or chopping sideways. No more guessing. No more stress. Just precision trades that put you in control.
Boston Scientific Closes Acquisition of Axonics, Inc.
See More Axonics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Axonics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Axonics and other key companies, straight to your email.

About Axonics

Axonics (NASDAQ:AXNX), a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retention (UR); and rechargeable (R20) and recharge-free (F15) implantable SNM systems that delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of OAB, UR, and FI. The company also offers Bulkamid, a urethral bulking agent to treat female stress urinary incontinence. It sells its products through a direct sales force and distributors in the United States, the United Kingdom, Germany, the Netherlands, Nordic countries, and internationally. The company was formerly known as Axonics Modulation Technologies, Inc. and changed its name to Axonics, Inc. in March 2021. Axonics, Inc. was incorporated in 2012 and is based in Irvine, California.

View Axonics Profile

More Earnings Resources from MarketBeat